UNSPSC 51101616: Melarsoprol

This classification denotes a trypanocidal agent and arsenical with the molecular formula C12H15AsN6OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZF3786Q2E8, chemically known as 1,3,2-dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)- but generally known as melarsoprol, which bears US NIH Compound Identifier 10311. European Medicines Agency schedules Melarsoprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08721MIG.

UNSPSC 51101616 Melarsoprol is a Commodity code that nominally describes a specific antiparasitic pharmaceutical, yet the recent state and local opportunities tagged under it do not reflect melarsoprol procurement. Instead, the code shows activity for broader pharmaceutical supply and emergency-response medical products. State and local health departments and county public-health agencies issue opportunities under this code, typically seeking bulk pharmaceutical inventory through cooperative purchasing vehicles or competitive bidding. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC for antibiotics (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets), and Seminole County, Florida sought annual supplies of Naloxone and drug deactivation systems through an Invitation for Bid. Neither opportunity aligns with the melarsoprol specification, suggesting either a coding mismatch in state procurement systems or a code assigned too broadly to pharmaceutical procurement generally.

Recent activity clusters in Florida and Illinois. The Illinois Department of Public Health contract, valued at $2,999,999.11 over 12 months with two renewal options, closed on September 11, 2026, and was awarded to Chartwell Rx LLC as the lowest-priced responsive and responsible bidder under an Invitation for Bid; the Seminole County procurement, posted June 30, 2026, sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to a county community health building. No set-aside or preference designations appeared in either record. The mismatch between the code's pharmaceutical specificity and the actual work solicited—which spans common antibiotics and emergency-response supplies—suggests caution in relying on this code to track melarsoprol-specific opportunities; vendors pursuing pharmaceutical supply in state and local markets should monitor broader health-department RFPs and cooperative purchasing consortia rather than expect consistent activity here.